Skip to main content
logo
Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
12.04
+0.45 (3.88%)
Nov 9, 2026, 10:45 AM EST - Market open

Zevra Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
147.76106.4723.6127.4610.1628.65
Revenue Growth
75.10%350.92%-14.02%170.26%-64.53%115.61%
Gross Profit
141.0389.9916.225.299.9426.59
Operating Income
46.5-4.23-87-49.6-24.97.73
Net Income
74.9777.59-105.51-46.05-26.77-62.9
Earnings Per Share
1.231.35-2.28-1.30-0.78-2.11
EPS Growth
128.31%-----

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
195.57191.0169.567.7482.85112.35
Total Debt
1.2363.2160.343.7714.131.61
Net Cash (Debt)
194.34127.819.223.9768.72110.74
Net Cash Growth
42.07%1289.18%-61.62%-65.11%-37.95%-
Net Cash Per Share
3.212.230.200.681.993.72

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
38.74-1.6-69.67-33.54-18.7210.44
Capital Expenditures
-0.46-0.84--0.3-0.09-0.1
Free Cash Flow
38.28-2.43-69.67-33.83-18.8110.34
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
95.44%84.52%68.59%92.09%97.81%92.81%
Operating Margin
31.47%-3.98%-368.47%-180.63%-245.07%26.98%
Pretax Margin
60.90%81.41%-381.76%-167.69%-263.80%-29.74%
Profit Margin
50.74%72.87%-446.85%-167.69%-263.48%-219.54%
FCF Margin
25.91%-2.28%-295.04%-123.20%-185.12%36.08%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
9.796.50----
Forward PE
12.6319.15102.50102.50102.5024.17
P/FCF Ratio
18.02----29.76
PS Ratio
4.674.7418.859.9015.5910.74